Danaher Corp.’s (NYSE: DHR) Leica Biosystems is buying Devicor Medical Products from Chicago private equity firm GTCR.
Devicor, headquartered in Cincinnati, makes medical devices that are used in breast biopsy procedures. Devicor makes products including the Mammotome Breast Biopsy System, tissue markers and related products that have been used for minimally invasive biopsies.
Devicor was formed by a management partnership with CEO Tom Daulton as part of GTCR’s theLeaders Strategy, under which the company partners with executives to build companies through acquisitions. The firm took over the Mammotome brand breast-care business from Johnson & Johnson (NYSE: JNJ) in 2010 and made several add-on acquisitions. For more about GTCR’s theLeaders Strategy, see the company’s profile as the winner of Mergers & Acquisitions’ 2013 M&A Mid-Market Award for Private Equity Firm of the Year.
Other recent deals by GTCR include: portfolio company Cision’s purchase of Grokana Group Ltd. earlier in October; and AssuredPartners Inc.’s acquisition of Casualty Assurance of Chaska, also in October.
Leica Biosystems provides workflow and automation services related to cancer diagnostics. Devicor will operate as a standalone business within Leica, and Daulton will remain CEO.
J.P. Morgan Securities LLC and Jefferies LLC served as Devicor’s financial advisers, while Kirkland & Ellis LLP provided legal advice.
For more on the health care sector, see 5 Technologies Drive Health Care M&A.